Retirement Systems of Alabama Has $22.28 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Retirement Systems of Alabama raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 23.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 389,268 shares of the biopharmaceutical company’s stock after acquiring an additional 74,173 shares during the quarter. Retirement Systems of Alabama owned about 0.31% of Halozyme Therapeutics worth $22,282,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Castellan Group lifted its holdings in Halozyme Therapeutics by 4.5% during the 3rd quarter. Castellan Group now owns 113,798 shares of the biopharmaceutical company’s stock worth $6,514,000 after purchasing an additional 4,876 shares during the last quarter. Tidal Investments LLC increased its position in Halozyme Therapeutics by 265.5% during the 3rd quarter. Tidal Investments LLC now owns 20,576 shares of the biopharmaceutical company’s stock worth $1,178,000 after buying an additional 14,947 shares during the period. World Investment Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the third quarter worth $3,293,000. Sanctuary Advisors LLC boosted its position in shares of Halozyme Therapeutics by 80.4% in the third quarter. Sanctuary Advisors LLC now owns 37,039 shares of the biopharmaceutical company’s stock valued at $2,120,000 after acquiring an additional 16,511 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at about $434,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Up 0.4 %

Shares of NASDAQ HALO opened at $48.00 on Friday. The company has a market cap of $6.11 billion, a price-to-earnings ratio of 15.89, a PEG ratio of 0.43 and a beta of 1.23. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53. The stock has a 50-day moving average price of $51.43 and a two-hundred day moving average price of $54.00.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $62.03, for a total value of $620,300.00. Following the sale, the senior vice president now owns 173,756 shares in the company, valued at $10,778,084.68. This trade represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 40,000 shares of company stock worth $2,242,100 in the last three months. 2.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

HALO has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $68.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, November 20th. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Piper Sandler increased their price target on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research report on Monday, November 4th. JMP Securities lifted their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Finally, Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $61.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.